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Between October 2001 and April 2002, five cases of acute flaccid paralysis (AFP) associated with type 2 vaccine-derived
polioviruses (VDPVs) were reported in the southern province of the Republic of Madagascar. To determine viral factors
that favor the emergence of these pathogenic VDPVs, we analyzed in detail their genomic and phenotypic
characteristics and compared them with co-circulating enteroviruses. These VDPVs appeared to belong to two
independent recombinant lineages with sequences from the type 2 strain of the oral poliovaccine (OPV) in the 59-half
of the genome and sequences derived from unidentified species C enteroviruses (HEV-C) in the 39-half. VDPV strains
showed characteristics similar to those of wild neurovirulent viruses including neurovirulence in poliovirus-receptor
transgenic mice. We looked for other VDPVs and for circulating enteroviruses in 316 stools collected from healthy
children living in the small area where most of the AFP cases occurred. We found vaccine PVs, two VDPVs similar to
those found in AFP cases, some echoviruses, and above all, many serotypes of coxsackie A viruses belonging to HEV-C,
with substantial genetic diversity. Several coxsackie viruses A17 and A13 carried nucleotide sequences closely related
to the 2C and the 3D
pol coding regions of the VDPVs, respectively. There was also evidence of multiple genetic
recombination events among the HEV-C resulting in numerous recombinant genotypes. This indicates that co-
circulation of HEV-C and OPV strains is associated with evolution by recombination, resulting in unexpectedly
extensive viral diversity in small human populations in some tropical regions. This probably contributed to the
emergence of recombinant VDPVs. These findings give further insight into viral ecosystems and the evolutionary
processes that shape viral biodiversity.
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Introduction
Polioviruses (PVs), members of the Enterovirus genus in the
Picornaviridae family, are major human pathogens causing the
acute paralytic disease poliomyelitis. The human enter-
oviruses (HEV) are classiﬁed into ﬁve species, HEV-A to -D,
and the PV species (PV-1 to 3). The species HEV-C includes
several serotypes of coxsackie A virus, and segregates in the
same phylogenetic cluster (cluster C) as the PV species [1].
Enteroviruses, including PVs, are small non-enveloped
viruses with a positive-strand RNA genome about 7.5 kb
long. The single large coding region of the genome is ﬂanked
by 59- and 39-UTR. The coding region is translated as a single
polyprotein that is processed by viral proteases to yield the
mature viral proteins including the capsid proteins VP1 to
VP4 and non-structural proteins including proteases and the
RNA-dependent RNA polymerase 3D
pol.
The World Health Organization’s program for global
eradication of poliomyelitis is based on immunization with
the oral PV vaccine (OPV). The attenuated OPV strains of the
three PV serotypes (Sabin 1, 2, and 3) replicate in the gut of
OPV recipients where they efﬁciently mimic natural infection
and thereby induce type-speciﬁc humoral and mucosal
immunity. This strategy has reduced the incidence of polio
w o r l d w i d eb yo v e r9 9 %s i n c et h es t a r to ft h eg l o b a l
eradication program in 1988, and has restricted wild PV
circulation to countries in western and central Africa and
southern Asia [2]. However, replication of OPV in humans is
frequently accompanied by genetic changes in the vaccine
virus. The changes can include reversion of key attenuating
mutations and acquisition of other mutations throughout the
genome. PV evolves very quickly, partly due to the high error
frequency in RNA synthesis: roughly 10
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to the variability of PV strains [4,5]. Intertypic recombination
is a frequent phenomenon in OPV vaccinees, and strains with
a recombinant genome have been isolated from both healthy
vaccinees and from patients with vaccine-associated polio-
myelitis [6–9]. The reversion of the OPV strains to neuro-
virulence is the underlying mechanism for the rare cases of
vaccine-associated paralytic poliomyelitis (VAPP) among
OPV recipients and their close contacts, and the occurrence
of polio outbreaks associated with circulating vaccine-derived
PV (VDPV) [10,11].
The ﬁrst outbreak of poliomyelitis (21 cases) associated
with VDPVs, was reported in 2000–2001, in the Dominican
Republic and Haiti [12]. Subsequently, outbreaks due to
VDPVs occurred in the Philippines, China, Indonesia,
Cambodia, Madagascar, and more recently in Myanmar and
Nigeria [13–17]. Prolonged circulation of type 2 VDPVs,
responsible for 30 cases of AFP from 1983 to 1993, has been
retrospectively demonstrated in Egypt [18]. The duration of
VDPV circulation before the outbreaks was estimated
through nucleotide divergence to be generally from about 1
to 2.5 years, however, it could reach 10 years in Egypt
[16,18,19]. Except in China, all VDPVs implicated in out-
breaks were recombinants originating from OPV strains; it
was suggested that large parts of the genomic regions
encoding the non-structural proteins in these strains were
derived from unknown non-polio enterovirus related to
HEV-C [11–16,18,20].
In most cases, low vaccine coverage is thought to have
allowed the circulation of OPV strains in non-vaccinated
children and the subsequent genetic and phenotypic drift of
these strains to pathogenic circulating VDPVs [16]. The
emergence of epidemic VDPVs threatens the success of the
program for global eradication of poliomyelitis. Improved
surveillance and vaccine strategies limiting VDPV spread are
urgently required. Other than low vaccine coverage, little is
known about the viral factors and conditions that favor the
emergence and circulation of VDPVs [16,19,21].
In Madagascar, type 2 recombinant VDPVs were identiﬁed
as the causative agent of ﬁve cases of poliomyelitis that
occurred from October 2001 to April 2002 [14]. We analyzed
the implicated VDPV isolates and compared their sequences
with those of co-circulating enteroviruses isolated from
healthy children living in the small area where most of the
poliomyelitis cases were reported. We demonstrate substan-
tial co-circulation and evolution of HEV-C and OPV strains
by recombination resulting in an unexpected genetic
diversity. This gives further insight into the characteristics
of viral ecosystems, evolution processes and factors that could
favor the emergence of pathogenic recombinant VDPVs.
Results
Sequence Analysis of the Madagascan VDPV Genomes
Five type 2 PV strains were isolated from stool samples of
each of the children with AFP collected in the Toliara (MAD
29 strain) and Tolagnaro (MAD 04, 05, 06, and 07 strains)
districts (Figure 1).
Overlapping reverse transcriptase (RT)-PCR products
covering the entire genome of each isolate were sequenced
(accession numbers for nt sequence data are given below).
The nt sequences of MAD 29, isolated in 2001, differed from
those of the other strains isolated in 2002. In contrast, the
genomes of the strains isolated during 2002 (MAD 04 to MAD
07) were closely related: MAD 04, 05, and 06 exhibited only 4
or 5 nt differences and MAD 07, the most divergent, differed
from the three others at 18 to 22 nt positions. Therefore, we
focused mainly on MAD 04, considered to be the 2002
prototype strain and on MAD 29.
The nt sequences of MAD 04, MAD 29, and the Sabin 2
strain were aligned and compared (Figure 2). Two different
genomic regions could be clearly distinguished: the 59-halves
of the genomes were all similar and appeared to be derived
from Sabin 2 with differences at few positions; in contrast,
Figure 1. Map of the Toliara Province in Madagascar
This map indicates the location of the two districts where the
poliomyelitis outbreaks occurred. Names of the PV strains isolated from
the patients with AFP are indicated.
doi:10.1371/journal.ppat.0030191.g001
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Co-Circulation of Polioviruses and HEV-C
Author Summary
Following extensive vaccination campaigns using the attenuated
oral polio vaccine, wild polioviruses remain endemic in only a few
countries. Nevertheless, several poliomyelitis outbreaks associated
with vaccine-derived polioviruses (VDPVs) were reported in different
parts of the world in recent years, particularly in Madagascar in 2002.
We analyzed the molecular characteristics of Madagascar VDPVs and
compared them with those of co-circulating enteroviruses. These
VDPVs appear to be recombinant viruses between vaccine polio-
viruses and human enteroviruses of species C (HEV-C) and to
present phenotypic characteristics similar to those of wild polio-
viruses including pathogenicity. Similar VDPVs and other enter-
oviruses, including several HEV-C of different types, were found in
the stools of healthy children living in neighboring villages to where
most of the poliomyelitis cases occurred. Some HEV-Cs showed
sequences closely related to those of VDPVs, indicating genetic
recombination between these viruses and vaccine polioviruses.
There was also evidence of multiple genetic recombination events
among other HEV-C isolates resulting in numerous different
genotypes. These findings indicate that co-circulation of HEV-C
and vaccine polioviruses and their evolution by recombination
results in unexpectedly extensive viral diversity, at least in some
small human populations, probably contributing to the emergence
of recombinant VDPVs. Results of this study give further insight into
the world of viruses and their biodiversity.the 39-halves of MAD 04 and MAD 29 diverged substantially
from that of the Sabin 2 genome.
The genomic region encoding the capsid protein VP1 (903
nt) is widely used in studies of the molecular epidemiology of
PV strains and in this region, MAD 04 and MAD 29 differed
from Sabin 2 by 23 and 9 substitutions, including 18 and 6
synonymous ones, respectively. Only three of these substitu-
tions were shared by MAD 04 and MAD 29. The general
molecular clock of PV has been estimated to be about 1% nt
substitutions per year from studies on circulating strains and
on viruses excreted from chronically infected immunodeﬁ-
cients [5,22–24]. A more precise estimation relies on the
percentage of substitutions per synonymous site. In partic-
ular, from the analysis of similar recombinant type 2 VDPVs
circulating in Egypt, the evolution rate of the capsid VP1
region appeared to be 2.5 (6 0.7).10
 2 substitutions per
synonymous site and per year [18]. This suggests that VDPVs
MAD 04 and MAD 29 had been circulating before isolation
for about 22 to 40 mo and 7 to 13 mo, respectively.
The non-vaccine part of MAD 04 and MAD 29 genomes
Figure 2. Genomic Features of the Poliovirus Isolates
(A) Plots of similarity between a set of aligned genomes (Sabin 2, MAD 04, MAD 29, and Sabin 1), using a 50-nt sliding window. Approximate nucleotide
positions in the poliovirus genome are indicated. Average nucleotide identities between the 59 vaccine part and the 39 non-vaccine part of the
recombinant genomes are shown.
(B) Sites of the recombination junctions in the recombinant VDPV genomes. The genetic organization of the PV genome is shown, including the 59- and
39-UTR. Genomic regions P1 to P3 encoding viral proteins (VP4 to 3Dpol) are indicated. Open and closed triangles indicate the approximate sites of the
recombination junctions of the MAD 29 and MAD 04 recombinant genomes, respectively. Both junctions are located at the 39 end of the protease 2A
genomic region. MAD 04 and MAD 29 sequences (nt 3651–3890) on both sides of the recombination junctions are given and compared with Sabin 2
sequences (S2). Nucleotide numbering according to Sabin 2 sequences is given in italics.
doi:10.1371/journal.ppat.0030191.g002
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Co-Circulation of Polioviruses and HEV-Cdiffered substantially from each other and from the Sabin 2
genome (from 12.9% to 16.5% nt; Figure 2). The percentages
of nt divergence were similar to those that differentiate the
39-halves of different PV or HEV-C genomes. For example,
the 39-half of the genome (3,730 nt) of Sabin 2 differs by
18.0% from that of the prototype strain G12 of coxsack-
ievirus A17 (CA17).
The sites of recombination in the genomes of the
Madagascan VDPVs, i.e., the junction between the vaccine
part and non-vaccine part of their genome, were in the
region encoding the C-terminal third of protease 2A (a 149-
amino acid protein). According to the sequence alignments
presented in Figure 2, the likely sites of recombination in the
genome of MAD 04 and other VDPV strains isolated in 2002
(MAD 05 to MAD 07) were all close to nt 3,801 (codon 139 of
2A). The likely site of recombination in MAD 29 was different,
and close to nt 3,708 (codon 108 of 2A).
The patterns of nt substitutions in the Sabin 2 regions of
the VDPV genomes, the sequences of the non-vaccine
genomic regions, and the positions of the recombination
sites between these two regions indicated that the PV strains
isolated in Madagascar in 2001 (MAD 29) and those isolated in
2002 (MAD 04 to 07) represented two different recombinant
VDPV lineages that had emerged and evolved independently.
Phenotypic Characteristics of the Madagascan VDPVs
The substitutions in the vaccine part of the VDPV genomes
are shown in Table 1. Some of them may have affected the
phenotype of the vaccine strain Sabin 2. To detect any effect
of these substitutions on antigenic structure, MAD 04 and
MAD 29 strains were compared to the Sabin 2 strain using a
Sabin 2 strain-speciﬁc monoclonal antibody (MAb) collection
(Table 2) [25,26]. Several MAbs directed against the neutral-
ization antigenic sites 1a and 3a of Sabin 2 had only weak
neutralizing effects on both strains MAD 04 and MAD 29.
Interestingly all MAbs directed against the antigenic site 2a
neutralized MAD 04 and Sabin 2 but did not neutralize MAD
29. In contrast, one MAb (MAb 1108) directed against the
neutralization antigenic site 3b showed a weak reactivity
against MAD 04 but neutralized both MAD 29 and Sabin 2.
Neither MAD 04 nor MAD 29 was neutralized by MAb 1233,
highly speciﬁc for Sabin 2, and used for intratypic analysis of
PV [27]. Thus, the antigenic structures of both VDPVs
differed from that of Sabin 2. Furthermore, the two strains
exhibited distinct neutralizing epitope maps, in agreement
with them representing two different VDPV lineages. The
location of amino acid mutations likely to be responsible for
the MAb reactivity of both VDPVs is shown in Table 1.
The plaque sizes of the VDPV strains isolated in Mada-
gascar were measured (Table 3). The VDPVs produced larger
plaques than the Sabin 2 strain (results signiﬁcant for four of
ﬁve VDPVs). We also tested the temperature sensitivity of the
VDPV by measuring the titers of the viral stocks at optimal
(36.0 8C) and supra-optimal (40.2 8C) temperature (RCT test:
Table 3). The non-temperature-sensitive and highly neuro-
virulent type 2 vaccine-derived environmental strain S2/4568
was used as control [28]. Unlike Sabin 2, the difference in titer
of all VDPVs and S2/4568 at these two temperatures was
small, indicating that they were not temperature-sensitive.
We also evaluated the pathogenicity of the Madagascan
VDPVs by IC and IP inoculation of groups of homozygous
PVR-Tg21 mice [29] with a single virus dose per animal
(Figure 3). In contrast to Sabin 2 that did not induce disease,
all the Madagascan VDPVs induced paralysis in all IC
inoculated animals. They were also all neurovirulent follow-
ing IP inoculation but the severity of the symptoms differed
between strains: strain MAD 04 was the most neurovirulent
strain and MAD 29 was the least neurovirulent strain. This
was conﬁrmed when the paralytic dose affecting 50% of the
inoculated mice (PD50) was determined by IC inoculation
(Table 3).
The Madagascan VDPVs did not have either the temper-
ature sensitive or attenuated phenotypes that characterize
the OPV strains, and therefore appeared to be similar to wild
PVs.
Search for VDPVs and Co-Circulating Enteroviruses in
Healthy Children of the Tolagnaro District
Following the VDPV outbreak, two rounds of local
vaccination campaigns with trivalent OPV were implemented
at 1-mo interval. Two weeks after the second round, 316 stool
specimens were collected from healthy children living in the
rural villages of the Tolagnaro district to check the effect of
these campaigns on the circulation of VDPVs. We also
exploited these samples to look for other enteroviruses and
to identify putative parents of the unidentiﬁed enterovirus
sequences present in the VDPV genomes. Healthy children
Table 1. Nucleotide Substitutions and Nonsynonymous Codon
Changes in the Vaccine Part of the Genome of the Madagascan
VDPVs
Genomic
Regions
Nt or a.a.
Position
a
Sabin 2 MAD 29 MAD 04 Phenotype
b
59 UTR 97 U C U
102 C C U
156 U C C
398 U C C
296 G C G
314 A A G
481 A G G Attenuation
646 U C U
650 U C U
656 A A G
690 U U C
VP4 34 Arg Arg Lys
42 Ser Ser Asn
VP2 115 Arg Lys Lys Near Ag site 3
VP3 75 Thr Thr Met Near Ag site 3
VP1 5 Met Met Ile
9 Ala Ala Thr
21 Pro Pro Leu
143 Ile Thr Thr Attenuation
171 Asn Asp Asp Near Ag site 1
218 Ala Thr Ala Ag site 2a
2A 28 Gln Arg Gln
33 Val Val Ile
42 Ala Thr Ala
123 Ile Ile Val
aNucleotide or amino acid positions. In the 59 UTR, all nucleotide positions differentiating
VDPVs from Sabin 2 are shown. In the capsid proteins region (VP4–VP1) and in the 2A
region, only nonsynonymous codon changes are shown. Amino acid positions are
indicated in italics.
bNucleotide or amino acid positions described as being involved in Sabin 2 attenuation or
antigenicity are labeled in bold [25,26,69–74].
doi:10.1371/journal.ppat.0030191.t001
PLoS Pathogens | www.plospathogens.org December 2007 | Volume 3 | Issue 12 | e191 1953
Co-Circulation of Polioviruses and HEV-Cwere recruited in the three villages where the AFP cases were
reported and in three nearby villages, all located in a swampy
coastal area, 2 to 8 kilometers away from each other (Figure 1
and Table 4).
Inoculation of cultured human RD and HEp-2c cells and
mouse L20B cells expressing the human PV receptor led to
the isolation from these samples of 23 PVs and 71 other
viruses inducing cytopathogenic effects only on human cells
[30–32] (Table 4). Sixty-eight non-polio viruses were identi-
ﬁed as enteroviruses by ampliﬁcation by RT-PCR of the 59
UTR regions using nt primers that target highly conserved
enterovirus sequences. The 59 UTR (nt 215–582, according to
Sabin 2 nt sequences numbering) and the regions encoding
the capsid protein VP1 (nt 3,067–3,376) and the nonstructural
proteins 2C (nt 4,123–4,383) and 3D (nt 6,145–6,732) of most
of the PV and other enterovirus isolates were sequenced.
From the isolation and sequencing data, no evidence of co-
infection by different enterovirus serotypes or genotypes was
found. However, re-inoculation of cells with positive samples
in the presence of neutralizing antibodies directed to the
identiﬁed virus serotype was not performed to check the
possible presence of a second one (see also Discussion
section).
Most PV isolates were closely related to one of the original
OPV strains with less than 0.5% nt divergence. However, one
of the non-recombinant type 2 OPV isolates was more
divergent, and the whole VP1 genomic region was sequenced:
it showed 0.7% nt divergence from the Sabin 2 sequence
(0.5%, in the three other genomic regions), indicating that
this strain had been multiplying or circulating for about 8
months. Two PV isolates were OPV type 3 / type 1 intertypic
recombinants, as commonly found in vaccinees [6]. Two type
2 isolates were closely related to the recombinant VDPVs of
the MAD 04 lineage with less than 1.1% nt divergence in all
sequenced genomic regions. Sequencing data of their whole
VP1 genomic regions indicated that these new VDPVs
(VDPVs 65972 and 68266) were slightly more divergent from
the Sabin 2 strain (2.8% and 3.1% nt divergence, respectively)
than their AFP counterparts (2.5%). Other than these two
recombinant VDPVs, the sequences of the PVs isolated from
healthy children provided no evidence of genetic recombi-
nation with non-OPV strains.
The nt sequences encoding the VP1 capsid protein of
enterovirus isolates contain serotype-speciﬁc information
[33–35]. We used partial sequencing of the capsid VP1 region
to identify 64 enteroviruses [33]. Several echoviruses of the
HEV-B species were found including two echoviruses
serotype 14 (E14), ten E19, and one E25. Surprisingly,
coxsackie A viruses (51 isolates) of the HEV-C species were
the most frequent, and they included 12 CA11, 16 CA13, eight
CA17, one CA20, and 14 CA24.
These ﬁndings indicated the persistence in the Tolagnaro
district of VDPV isolates of the MAD 04 lineage despite two
rounds of vaccination; they also show that many children
were excreting non-poliovirus enteroviruses (21%) in partic-
ular HEV-C (16%).
Genetic Relationship between the VDPVs and the Other
Enteroviruses Isolated in the Tolagnaro District
The various enterovirus sequences were aligned and
compared in phylogenetic trees. The phylogenetic relation-
ships between the Madagascan HEV-C ﬁeld isolates, their
prototype strains, OPV strains, and the VDPVs isolated in the
island and in other countries are shown in Figure 4. The four
last wild PV strains isolated in Madagascar, two type 1 strains
(PV1.Mad96a and PV1.Mad96b) isolated in 1996 and two type
3 strains (PV3.Mad95 and PV3.Mad97) isolated in 1995 and
1997, respectively, were included. For phylogenetic trees,
similar assignments for reconstruction of major clusters and,
in most cases, of sub-clusters were obtained using both the
Table 2. Antigenic Structure of the VDPVs MAD 04 and MAD 29
Antigenic Site
a MAb Strain
b
Sabin 2 MAD 04 MAD 29
1a 268 .1024 1024 1024
(VP1 93–101, 105, 174) 269 256 128 128
435 512 16 16
437 512 16 16
467 .1024 1024 1024
969 1024 ,16 ,16
2a 1231 512 512 ,16
(VP1 217–221 ; VP3 140) 1234 256 128 ,16
1246 .1024 .1024 ,16
1247 .1024 256 ,16
1251 .1024 1024 ,16
1268 1024 256 ,16
2b (VP2 167–168) 1037 .1024 .1024 .1024
3a 1051 1024 512 512
(VP2 72–73, 239, 244; VP3 207) 1102 .1024 .1024 .1024
1103 512 256 512
1117 1024 512 1024
1233 512 ,16 ,16
3b 697 .1024 .1024 .1024
(VP2 158 ; VP3 56, 61, 66) 1050 .1024 .1024 .1024
1059 .1024 .1024 .1024
1108 .1024 32 .1024
aSites and amino acids known to contribute to the constitution of neutralization antigenic
sites (1a to 3b) are given [25,26,72–74].
bA given amount of the indicated virus strain (100 TCID50) was incubated with serial
dilutions of various monoclonal antibodies reacting with Sabin 2. The highest dilutions
that neutralized the analyzed viruses are given. Values indicating poor neutralization or
no neutralization at all are shown in bold.
doi:10.1371/journal.ppat.0030191.t002
Table 3. Phenotypic Markers of the VDPVs and Other Poliovirus
Strains
Virus
Strain
Plaque
Sizes
a,m m
RCT D log10
TCID50/ml
(36.0 8C – 40.2 8C)
Paralytic Dose 50
(log10 TCID50/
Mouse)
Sabin 2 0.5 (0.2) 4.2 . 6.6
S2/4568 1.1 (0.4) 0.9 , 3.3
MAD 04 2.2 (0.6) 0.0 3.5
MAD 05 1.8 (0.6) 0.3 ND
b
MAD 06 1.8 (0.7) 0.5 ND
MAD 07 0.9 (0.4) 0.9 ND
MAD 29 2.2 (1.1) 1.3 4.6
aMean plaque diameters (mm) following incubation at 34 8C for 72 h on HEp-2c cells are
indicated; the standard deviation is shown in brackets.
bND: not done.
doi:10.1371/journal.ppat.0030191.t003
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Co-Circulation of Polioviruses and HEV-Cmaximum likelihood and the genetic distance matrix /
neighbor-joining methods.
As expected, the sequences of the two VDPVs isolated from
healthy children (VDPVs 65972 and 68266) clustered with
those of the VDPVs MAD 04 and MAD 07 in the four
phylogenetic trees (Figure 4) conﬁrming that they belong to
the same recombinant lineage.
According to VP1 sequences, HEV-C isolates displayed
different patterns of genetic diversity depending on their
serotype. CA13 and CA11 isolates appeared to be relatively
heterogeneous: 83 to 100% VP1 nt identity within their
respective clusters, and different sub-clusters could be
observed. VP1 sequences of most CA17 and CA24 isolates
were more homogeneous with 91%–98% nt identity within
their respective clusters. However, isolates CA17.67610,
CA24.65902, and CA24.68098 showed only 83%–85%, 72%–
75%, and 75%–88% nt identity with their respective
counterparts. Therefore, the VP1 nt sequences of these
coxsackie A virus isolates showed a relatively high genetic
diversity within each of their respective serotypes.
In contrast to VP1 sequences, the nt sequences of the N-
terminal part of protein 2C did not necessarily segregate
according to the serotype of the isolate. The 2C sequences of
the VDPVs of the MAD 04 lineage segregated neither with
those of the Sabin 2 strain nor with those of other OPV strain
serotypes but with those of the major group of CA17 ﬁeld
isolates (92%–94% nt identities; high reliability values). This
result strongly suggests that a MAD 04 VDPV ancestor has
acquired its non-OPV 2C sequences from a co-circulating
CA17 isolate by genetic recombination or that both viruses
acquired these sequences from a common ancestor virus.
These VDPVs also showed relatively high nt identities (91%–
93%) with the wild PV1.Mad96a and appeared related to a
certain extent to the two other wild PV1.Mad96b and
PV3.Mad97 (86%–90% nt identities) and to the other VDPV
MAD 29 (86%–87% nt identities). No other major change
appeared in the groupings of the 2C phylogenetic tree
compared to the groupings of the VP1 tree, except for the
isolate CA24.67897 whose 2C sequences were distantly related
to those of the other ﬁeld CA24 isolates (labeled by dotted
lines in Figure 4) indicating that this isolate had acquired its
2C sequences by intratypic recombination.
There were major differences between the groupings of
isolates in the phylogenetic tree of the 3D nt sequences and
those in the VP1 and 2C trees (Figure 4). The 3D sequences of
many isolates, in particular those of the CA11, CA13, and
CA17 ﬁeld isolates, appeared to be split into distantly related
clusters. VDPVs of the MAD 04 lineage showed 3D sequences
closely related to those of four CA13 isolates (92%–93% nt
identities; high reliability values). They were related to
PV1.Mad96a (90% nt identity) and to a certain extent to
two CA13, to PV1.Mad96b and to VDPV MAD 29 (87%–88%
nt identities). The other CA13 isolates and all CA17 isolates
were more distant (81%–85% nt identities). Recent intertypic
recombination events could be inferred. In particular, the
cluster containing CA13.68132, CA17.68138, CA17.68146, and
CA17.67591 (99% nt identities; high reliability value), and
that with CA13v.67900, CA11v.68123, and CA11v.68129 (94%
nt identities) indicate genetic exchanges between CA13 and
CA17 isolates and between CA11 and CA13 isolates.
According to the phylogenetic tree built with the 59 UTR nt
sequences, the isolates belonging to each of the major
serotypes (CA11, CA13, CA17, and CA24) were in different
clusters. This indicates that the 59 UTR of these serotypes has
frequently been subject to recombination.
In order to estimate the number of different recombinant
lineages among the Madagascan HEV-C isolates, we system-
atically considered incongruences between the four different
phylogenetic trees (Figure 4) that were supported by reliable
values and/or observed using both the maximum likelihood
and the genetic distance matrix/neighbor-joining methods. 19
HEV-C recombinant lineages differing by one of the
sequenced fragments could be distinguished. In most cases,
a good correlation was found between recombinant lineages
and groups or subgroups of nt sequences observed in a single
tree (as mentioned above for the VP1 tree). Different
serotypes and in some cases different recombinant lineages
belonging to the same serotype were found in the same
village. Moreover, a given recombinant lineage could be
isolated in two different villages.
We compared the polypeptides encoded: the peptide
relationships did not necessarily parallel the nt relationships.
The 2C-polypeptides (87 residues) of the Madagascan VDPVs
of the MAD 04 lineage differed from those of the closely
related CA17 ﬁeld isolates at one to two amino acid positions.
They were strictly identical to those of PV1.Mad96a and
PV1.Mad96b, to those of some other CA17 and CA11 isolates
and even to those of some VDPVs isolated in other countries
but different from the 2C peptide sequences of other ﬁeld
isolates (16 to 17 amino acids differences for the CA13 ﬁeld
Figure 3. Neurovirulence of VDPVs in Transgenic PVR-Tg Mice
A given dose of virus was used to inoculate intracerebrally (IC) or
intraperitoneally (IP) groups of PVR-Tg mice expressing the human
poliovirus receptor (8–10 animals per virus). Animals were checked daily
for 14 d following inoculation for paralysis and death. Percentages of
affected mice following inoculation of viruses MAD 04 to MAD 07, MAD
29, and of a positive neurovirulent control virus S2/4568 are given. Strain
S2/4568 was used only for IP inoculation. IP or IC inoculation of the
vaccine strain Sabin 2 did not induce disease in animals.
doi:10.1371/journal.ppat.0030191.g003
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Brown et al. [36] indicating that the 2C peptide sequences of
prototypes CA17, CA11, and CA20 are particularly similar to
those of PVs. As expected, the peptide sequences of the 3D
regions (196 residues) are highly conserved for all serotypes
and even the 3D amino acid sequences of the prototype
strains CA13 and CA24, as well as those of some HEV-C ﬁeld
isolates or those of the wild PV1.MAd96a are strictly identical.
The 3D polypeptides of the MAD 04 lineage differed from
those of the four most closely-related CA13 ﬁeld isolates at
two to ﬁve amino acid positions, those of their most divergent
HEV-C ﬁeld isolates (nt level) showing no more than six
different amino acids. These results conﬁrmed that viral 2C
and particularly 3D HEV-C polypeptides are highly con-
served. They are probably poorly permissive to most amino
acid modiﬁcations acquired by mutations or recombination.
The corollary of this is that conserved peptidic sequences
could favor genetic exchanges.
Although the genetic exchanges between these enter-
oviruses appeared to have a limited effect on the variability
of the peptide sequences, our ﬁndings indicated a substantial
genetic diversity of HEV-C isolates in the Tolagnaro district
due to nt divergence as well as to intertypic and interspeciﬁc
recombination involving PV. As expected, phylogenetic
analysis of the nt sequences of the HEV-B isolated in
Madagascar yielded evidence of interspeciﬁc recombination
events neither between the VDPVs and the three serotypes of
HEV-B isolates (Figure S1) nor between HEV-B and HEV-C
isolates (not shown).
Discussion
Here, we describe two different lineages of type 2 PV/HEV-
C recombinant VDPVs that appeared and circulated inde-
pendently in Madagascar, and that induced paralytic polio-
myelitis. The search for enterovirus circulating in the small
area where most of the poliomyelitis cases occurred indicated
an unexpectedly high diversity of coxsackie A viruses
belonging to HEV-C that co-evolved by intertypic and
interspeciﬁc recombination involving PVs.
Circulation of endemic type 2 VDPVs and wild strains
associated with low vaccine coverage in Egypt from 1983 to
1993 has been described [18]. The isolates appeared to be
derived from a single OPV infection and all belong to the
same lineage. The speciﬁcities of the outbreak we describe are
that it occurred in a country where wild PV strains were
eliminated by 1997 and that it was due to two different type 2
VDPV lineages.
Studies that established the rates of infection and indirect
immunity against PV in contacts of vaccinees indicate that
the Sabin 2 strain spreads to unvaccinated children more
easily than type 1 and 3 vaccine viruses [37–39]. Sabin 2 is
highly immunogenic in vaccinees and induces higher sero-
conversion rates than do the other two OPV serotypes
[38,40,41]. Nevertheless, the Sabin 2 strain also has the bad
reputation of inducing the highest rate of VAPP following
contact with vaccinees [9,42]. These characteristics, may
explain why Sabin 2-derived viruses can in some circum-
stances, circulate in human populations and subsequently
acquire pathogenic characteristics [43]. The discovery of two
different lineages of type 2 VDPVs in Madagascar conﬁrms
this notion. Furthermore, new lineages of type 2 VDPVs were
isolated from AFP cases in the southern part of Madagascar in
2005 (Rakoto Andrianarivelo et al. unpublished data and
[44]). Very recently, numerous poliomyelitis cases due to
different type 2 VDPV lineages were reported in Nigeria, a
country still endemic for wild PVs [17,45].
We report two VDPV isolates genetically similar to the
MAD 04 lineage and isolated 2 months after the last AFP case
and following two rounds of local vaccination campaigns; this
indicates that this type 2 VDPV lineage was widespread and
well established in the population and has not been cleared
by these campaigns. However, two weeks after the second
local round of vaccination only 7% of children were found to
excrete Sabin-like PVs. Previous immunisation responses may
have limited subsequent multiplication and excretion of
vaccine strains, and numbers of excretors [39]. However, we
cannot exclude the possibility that interference between OPV
strains and the numerous endogenous enteroviruses circulat-
ing in the province, or some other host and environmental
factors contributed to reducing vaccine strain multiplication
and to limiting OPV immunogenicity [40,41]. Unfortunately,
no data concerning OPV responses following the local
vaccination campaigns were available. However, no further
AFP cases due to this VDPV lineage have been reported in the
area. This lineage is thought to have disappeared, possibly
after the two national rounds of vaccination (‘‘national
immunization days’’) that followed in September and
October 2002.
The characterization of the enteroviruses co-circulating
Table 4. Epidemiological and Virological Data for the Healthy Children
Villages
a Stool Samples (Number) Mean Age (y) Sex Ratio M:F  3 Routine OPV Doses (%)
b PV1 Polio
c PV2 PV3 NPVI
d
Ambanihazo 28 1.9 1.0 0 1 2 3 4
Esohihy 9 5.7 3.5 11.1 0 0 1 1
Ebakika 173 4.6 0.7 13.4 0 2 6 36
Iaboakoho 24 1.6 0.6 29.2 0 0 4 3
Vatomirindry 54 3.2 0.7 1.9 0 0 0 22
Mahatalaky 28 2.3 0.8 17.9 0 1 3 5
Total 316 3.7 0.8 11.7 1 5 17 71
aVillages in the Tolagnaro district where AFP cases were reported are shown in bold.
bNote that these values do not take into account the OPV doses received during the local vaccination campaigns organized in response to the outbreak.
cNumber of poliovirus (PV) isolates: serotypes 1, 2, and 3 are indicated. These results include the two VDPVs isolated in Ebabika and Mahatalaky, respectively.
dNumber of non-polio viral isolates (no growth on L20B cells) including 68 enteroviruses.
doi:10.1371/journal.ppat.0030191.t004
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that both the frequency and diversity of HEV-C were
substantial. Five of the six HEV-C serotypes known to grow
in cultured cells were found (three serotypes can only be
isolated in new-born mice) [36]. Moreover, the genetic
diversity within each serotypes was high due to nt sequences
divergence and number of subgroups distinguished and to
frequent recombination events involving all four sequenced
regions (19 different recombinant lineages differing by one
sequenced fragment). Similar evolution processes, involving
frequent intertypic recombination, have already been de-
scribed mostly for HEV-B [46–52] and PVs [5,8,53,54]. In this
study we show that recombination also contributes consid-
erably to the genotypic diversity of HEV-C. Different HEV-C
serotypes circulate in Cambodia and a previous study has
pointed the relatively high frequency and the wide distribu-
tion of HEV-C in different regions of Madagascar [32,53].
However, this is the ﬁrst time that such a high frequency and
diversity of HEV-C isolates, and, in general, of isolates of the
same RNA virus species, have been described in such a small
Figure 4. Phylogenetic Trees Depicting Genetic Relationships between Nucleotide Sequences of Enteroviruses of the HEV-C Species
These neighbor-joining trees were based on nucleotide sequence alignments of part of the 59 UTR, the C-terminal third of the VP1-coding regions, part
of the 2C-coding regions, and of the 3D
pol regions. Branch lengths were calculated using PUZZLE and the Hasegawa, Kishino, and Yano (HKY) model of
substitution [63]. The genetic distance is indicated (bar). Numbers at nodes correspond to the percentage of 25,000 puzzle steps supporting the distal
cluster; numbers in italics representing the percentage of 1,000 bootstrap pseudoreplicates obtained with the DNADist/Neighbor and SEQBOOT
programs of PHYLIP [65] are shown in several cases. Sequences of some of the last wild PV strains (PV3.Mad95, PV1.Mad96a, PV1.Mad96b, and
PV3.Mad97) isolated in Madagascar (1995–1997) were used in addition to HEV-C prototype strains (CA1 to CA24). Selected PV strains isolated during the
last poliomyelitis outbreak in Finland (PV3.Fin84) and during the recent VDPV outbreaks in Egypt (PV2.Egy93; PV2.Egy88), Haiti (PV1.Hai00), Dominican
Republic (PV1.Dor00), and the Philippines (PV1.Phi01) are included. Sequences of the recombinant type 3 PV isolated from a poliomyelitis case in
Cambodia in 2002 (PV3.Cam02) were also used. Nucleotide sequences of echovirus 70 (EV70) were used as outgroup. Identifiers of the HEV-C coxsackie
A viruses isolated from healthy children in 2002 in Madagascar consist of the given serotype as assessed from partial sequencing [33] and the laboratory
number. New VDPV isolates from healthy children are indicated with their laboratory numbers. Spots of different colors differentiate HEV-C serotypes
and polioviruses (red). VDPVs from Madagascar are indicated by oblong spots. According to the Eight Report of the ICTV [56], former CA15 and CA18
are considered as antigenic variants of CA11 and CA13, and are now named CA11v and CA13v, respectively. All field isolates from Madagascar, except
isolates CA24.65902 and CA24.68187, were sequenced in the four regions. Vertical dotted lines indicate groups of isolates of particular interest that are
discussed in the text.
doi:10.1371/journal.ppat.0030191.g004
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Co-Circulation of Polioviruses and HEV-Carea (about 25 3 10 Km) and in such a small population (316
children). Our observations thus shed a new light on the
characteristics of viral ecosystems and their evolution.
Most VDPV strains described as OPV/HEV-C recombinants
were isolated in countries in which wild PVs have been
eradicated, so the unidentiﬁed human enterovirus has been
presumed to be HEV-C [11,12,14–16,18,20]. Up to now only a
Sabin3/HEV-C recombinant from Cambodia was shown to be
directly related to indigenous CA17 strains in the 2BC
genomic region and to a CA13 isolate in the 3D region [53].
Here we show that recombinant VDPVs are similarly closely
related to CA17 isolates in the 2C region and to CA13 isolates
in the 3D region. These ﬁndings indicate that CA17 and CA13
isolates are particularly suitable partners for sharing nt
sequences with PVs by means of recombination. Moreover,
this study indicates for the ﬁrst time that HEV-C isolates
sharing sequences closely related to a VDPV lineage were co-
circulating with this lineage in the very place where the
outbreak occurred. These observations lend considerable
support to the idea that there is frequent genetic recombi-
nation between OPV strains and at least some HEV-C
serotypes, and that this plays a role in the emergence and/
or evolution of VDPVs.
Despite the recombinant OPV/HEV-C features of most
VDPVs, ﬁeld isolates with the capsid of HEV-C and non-
structural parts from OPV were not found in this study. To
our knowledge such recombinants have not been described
elsewhere. The viral replication machinery or selection
factors that are known to act in vivo to shape the features
of intertypic OPV recombinant genomes [6] may exclude
such HEV-C/OPV recombinants. This hypothesis was recently
supported experimentally with recombinant viruses gener-
ated from PVs and CA20 or CA21 prototype strains [55].
Genetic recombination requires the co-infection of the
host and cells by at least two parental viruses. In fact, search
for viral mixtures was not the primary goal of the study and
the viral isolation procedures were poorly adapted to detect
them. However, recent inoculation of HEp-2c cells and RD
cells with almost all PV positive samples, in the presence of a
mixture of neutralizing antipoliovirus antibodies, indicated
that about 25% of these samples contain at least one other
enterovirus serotype that was masked on L20B cells during
PV isolation (not shown).
It is interesting to note that the nt sequences of the CA17
and the CA13 isolates that are closely related to those of the
MAD 04 lineage are also related to a certain degree to the
sequences of the VDPV MAD 29 and, despite at least 5 y of nt
drift, remain related to sequences of wild PVs isolated in 1996
and 1997. Relationship between these isolates probably
results from co-circulation of these viruses and evolution by
recombination since many years throughout the Tolagnaro
Province. This suggests that PVs and HEV-C have been
occupying the same or at least overlapping viral ecological
niches, both species contributing to evolution and the
generation of diversity by intratypic, intertypic and inter-
speciﬁc recombination. These various considerations argue
for a long-term evolution process involving wild or vaccine
PVs and some HEV-C viruses (at least CA17 and CA13) and
lend support to the proposal that PVs and HEV-C should be
considered to be members of a single species [5,36,55,56].
The functional role of interspeciﬁc genetic exchange in the
evolution of PV/HEV-C recombinants is still unclear. Type 1
non-recombinant and vaccine/vaccine recombinant VDPVs
have circulated for about one year in China and in Romania,
respectively, showing that recombination with HEV-C is not
essential for OPV strains to become circulating VDPVs
[13,57]. Nevertheless, recombination frequency suggests that
genetic exchanges may allow PV and HEV-C to evolve rapidly
and to acquire some functions like those that are necessary
for efﬁcient circulation in the population. Although less likely
we cannot exclude that interspeciﬁc recombination may be a
neutral phenomenon and simply testify that OPV and HEV-C
strains are well established in the population thereby
increasing considerably the frequency of encounters and
recombination. Indeed, the frequency of HEV-C circulation
is high in both Madagascar and Cambodia, countries in hot
humid tropical zones [32,53]. Possibly, the climate along with
sanitation and hygiene are important risk factors for VDPVs
and enterovirus spread. It is also plausible that particular
physiological, immunological and genetic factors in the local
human population help these viruses circulate and co-evolve.
To our knowledge, the observed HEV-C frequency and
biodiversity and the simultaneous presence of VDPVs in such
small areas and such small human populations have not
previously been described. This biodiversity combined with
the poor polio vaccine coverage, may make the local
ecosystem a ‘‘cauldron’’ particularly favorable for the
emergence of new recombinant VDPVs and possibly new
pathogenic coxsackie A virus strains. This argues strongly for
an increased surveillance in such areas and for the contin-
uation of studies to elucidate the viral, human and environ-
mental factors that shape viral genetic diversity and
contribute to the emergence of VDPVs.
Materials and Methods
Cells and viruses. Human HEp-2c, RD cells, and murine L20B cells
(murine L cells expressing the PV human receptor [31]) were grown
as monolayers in Dulbecco’s modiﬁed Eagle medium supplemented
with 5% fetal calf serum.
The poliovaccine viruses, Sabin 1, 2 and 3 were obtained from the
WHO [Behringwerke (S0þ1)] ‘‘master seeds’’. The second passage at
34 8C in HEp-2c cells of the original seed was used to prepare viral
stocks.
VDPVs MAD 04 to MAD 07 and MAD 29 were isolated on human
RD and murine L20B cells from specimens (stools) from poliomyelitis
cases according to WHO recommendations for poliomyelitis surveil-
lance.
PV strain S2/4568 has been described previously: it is a highly
neurovirulent and non-temperature sensitive vaccine-derived strain,
of serotype 2 [28].
Field investigations. To determine the frequency and circulation
of VDPVs ﬁeld investigations were conducted on June 21 and 22 in
rural villages of the district of Tolagnaro. 316 stool specimens were
collected among healthy children. A baseline questionnaire, which
included date of birth, sex, site of enrolment, and previous routine
immunization based on health cards, was completed for each child.
This investigation was conducted as part of the national AFP
surveillance recommended by WHO for poliomyelitis surveillance
purposes. It was organized with the agreement and help of the
Madagascan Ministry of Health and Family planning and biological
materials were collected after obtaining informed consent from the
parents.
Viral isolation. Extracts of stool specimens were treated with
chloroform and used to inoculate RD and HEp-2c cell lines, for
enterovirus isolation, and L20B cells. All L20B PV isolates were
characterized using microneutralization serotyping tests [30]. Isolates
showing cytopathogenic effects only on HEp-2c or RD cell lines were
considered to be non-polioviruses and analyzed further by molecular
typing (see below).
Poliovirus isolates were analyzed by multiple restriction fragment
length polymorphism assays involving ampliﬁcation of two regions of
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pol-39-UTR) and
the restriction enzymes DpnII, DdeI, HinfI and RsaI as previously
described [58]. Strains identiﬁed by this method as mutant and
recombinant PV vaccine strains were further analyzed by partial
sequencing.
RT-PCR. Viral RNA was reverse transcribed as described previously
either directly from viral stocks, following heat denaturation of the
virions [8], or following viral RNA extraction [49]. DNA fragments
were ampliﬁed by PCR as described by Chevaliez et al. [49] using
previously described primers [8,33,49]. Depending on the presence of
a single or multiple bands in the gel, pooled PCR products (100 ll)
were either directly puriﬁed using the QIAquick PCR Puriﬁcation kit
(Qiagen) or excised from agarose gel following electrophoresis and
puriﬁed with the QIAquick Gel Extraction kit (Qiagen).
The 59-end of the viral genome was ampliﬁed with the 59/39 RACE
kit (Roche), as described in the manufacturer’s protocol. Brieﬂy, viral
RNA was used for ﬁrst-strand cDNA synthesis using the primer UC52
[8]; the cDNA was puriﬁed and a dA-tailing reaction was carried out.
We then ampliﬁed the dA-tailed cDNA by PCR using the primer
UC52 and oligo-dT.
Sequencing. The ampliﬁed DNA fragments were directly se-
quenced using the Big-Dye Terminator Cycle Sequencing Ready
Reaction Kit on the ABI Prism DNA 377 Sequencer (Perkin-Elmer
Applied Biosystems) according to the manufacturer’s protocol and
using primers described in Guillot et al. and Caro et al. [8,33].
Alternatively, conditions for RT-PCR ampliﬁcation and cycle
sequencing were as described previously [18], using the primers
listed in Yang et al. and Kew et al. [12,18]. Sequencing was performed
in both directions, and every nt position was sequenced at least once
on each strand.
Molecular typing of enteroviruses. A fragment of 299 to 322 bp
corresponding to the 39 third of VP1 capsid was compared with the
corresponding region of available prototype sequences, using the
CLUSTAL W alignment program [59]. The GenBank database was
also screened for similar sequences using the FASTA program [60].
Scores were established for each strain according to nt identity and
amino acid similarity with the closest prototype strains. The serotype
of the ﬁeld isolates was assumed to be that of the closest prototype
strain according to the results of pairwise comparisons of nt
sequences, as previously described [33]. In most cases, nt identities
with the homologous prototype strains were higher than 75% [33].
However, for many CA24 isolates, nt identities were between 71%
and 75%. In this case the putative serotype was supported by the
serotype associated with the most similar enterovirus nt sequences
present in data banks, usually giving higher nt identities (.75%).
Coxsackie A viruses serotypes 15 and 18 are now considered as
antigenic variants of coxsackie A virus serotype 11 and 13 and are
named in this work CA11v and CA13v, respectively [56].
Alignment of sequences and phylogenetic analysis. Phylogenetic
relationships between strains were established by comparing the
sequences determined and aligning them with those of other known
human enteroviruses, using the alignment program ClustaL W or
Clustal X [59,61]. The degree of nt sequence identity and of protein
similarity between strains was determined using the default scoring
matrices.
Complete genome sequences were compared following alignments
with the plot-similarity program of GCG version 10.1 software
(Genetics Computer Group, Madison, Wisconsin), using a 50-nt
sliding window and the default scoring matrix [62].
Phylogenetic relationships between sequences were inferred by the
maximum likelihood method with PUZZLE 4.0, which uses QUAR-
TET PUZZLING as the tree search algorithm [63]. The Hasegawa,
Kishino, and Yano (HKY) model of substitution for nt with a Ts/Tv of
8.0 was used [64]. Trees were constructed using neighbor-joining of
PHYLIP (Phylogeny Inference Package) version 3.6 [65] and branch
length given by Puzzle. The reliability of tree topology was estimated
using 25,000 puzzle steps.
Alternatively, phylogenetic relationships were inferred by DNAD-
ist/Neighbor of PHYLIP [65] and a genetic distance matrix was
calculated using the F84 model of nt substitution with a transition/
transversion ratio (Ts/Tv) of 8.0. The robustness of phylogenies was
estimated by bootstrap analyses with 1000 pseudoreplicate data sets
generated with the SEQBOOT program.
Trees were drawn with the TREEVIEW [66] or NJ Plot programs
[67].
Temperature sensitivity. The temperature sensitivity of viruses was
evaluated by studying the reproductive capacity of each virus strain at
various temperatures (standard RCT test). RCT is deﬁned as the
difference between the log10 virus titer of a viral stock measured at
36.08C and that at 40.28C. Titers were determined on RD cells by an
endpoint micromethod after 5 days of incubation at the appropriate
temperatures, and are expressed in TCID50 per ml [68]. Viruses with
RCT values above 2 were considered to be temperature sensitive. See
also Supporting Information for details (Protocol S1).
Virus plaque sizes. Plaque diameter was determined by using virus-
infected HEp-2c cells maintained under a 0.9% agarose overlay and
stained after 3 days of incubation at 34 8C, in a 4% CO2 incubator.
For each virus, the diameter of all isolated plaques (about 30 plaques)
was measured and mean plaque diameter and standard deviation
were calculated (Protocol S1).
Antigenic structure analysis. The antigenic properties of viruses
were studied by a microneutralization assay as previously described
[25,26] using PV Sabin-speciﬁc MAbs corresponding to antigenic sites 1
to 3. One hundred TCID50 of the challenge virus were used in the test.
Assay of neurovirulence in PVR-Tg mice. Viruses were tested for
neurovirulence in homozygous PVR-Tg21 mice which are susceptible
to PV infection (generous gift from A. Nomoto) [29]. Groups of ten
PVR-Tg21 mice (5 males and 5 females) were inoculated intra-
cerebrally (ic; 40 ll) and intraperitoneally (ip; 1 ml) with a single dose
of virus (7 and 8 Log10 TCID50/mouse, respectively). Challenged mice
were monitored daily for 14 days and clinical symptoms (paresis,
paralysis, or death) recorded for each mouse.
For evaluating the viral dose that induced paralysis or death in
50% of mice (PD50) groups of eight (4 males and 4 females) 5- to 6-
week-old mice were used. Animals were inoculated (IC) with 40 llo f
tenfold dilutions in Dulbecco’s modiﬁed Eagle medium of virus stocks
containing 0.1% fetal calf serum. Mice were inoculated to cover the
viral titer range, causing disease in 100 to 0% of mice. In some cases,
although the viral suspension with the highest or lowest titer available
was used, the 100% or 0% paralytogenic dose could not be attained.
To conﬁrm the inoculated dose, viral suspensions were back-titrated
after inoculation. Inoculated mice were monitored for 21 days and
the PD50 was calculated by the method of Reed and Muench [68]. All
experiments were conducted in full compliance with French
regulations regarding laboratory animal welfare. Protocols were
approved by the Veterinary Staff of the Central Animal Facility of
Institut Pasteur.
Supporting Information
Figure S1. Phylogenetic Trees Depicting Genetic Relationships
between Nucleotide Sequences of Enteroviruses of the HEV-B
Species and PVs
These neighbor-joining trees were based on nucleotide sequence
alignments of different part of the genomes and built as described for
Figure 4. Sequences of selected HEV-B, echovirus prototype strains
(E14, E19, and E25) are included.
Found at doi:10.1371/journal.ppat.0030191.sg001 (1.5 MB PDF).
Protocol S1. Temperature Sensitivity and Viral Plaque Sizes
Found at doi:10.1371/journal.ppat.0030191.sd001 (46 KB DOC).
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